Int J Biol Sci 2011; 7(6):815-822. doi:10.7150/ijbs.7.815 This issue


A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!

Zhiyong Guo, Yun Qiu

Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See for full terms and conditions.
Guo Z, Qiu Y. A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!. Int J Biol Sci 2011; 7(6):815-822. doi:10.7150/ijbs.7.815. Available from

File import instruction


Prostate cancer is the second leading cause of cancer-related death in American men. Although most prostate cancers are initially androgen-dependent and respond to androgen ablation therapy, majority of them eventually relapse and progress into incurable castration-resistant (or hormone refractory) prostate cancer. The underlying mechanisms are the focus of intensive investigation for development of more effective treatment. Mounting evidence from both clinical and basic research has demonstrated that the activity of the androgen receptor (AR) is still required for castration-resistant prostate cancer. Multiple mechanisms by which AR is re-activated under androgen-depleted conditions may be involved in the development of castration resistance. The recent identification of AR splicing variants may add another layer of complexity in AR biology. The present review summarizes recent progress in study of AR splicing variants in prostate cancer.

Keywords: androgen receptor, prostate cancer, splicing variants, alternative splicing.